Clinical experience with exenatide in a routine secondary care diabetes clinic

Natarajan, B.; Edavalath, M.; Davies, J.; Jenkins, L.; Marshall-Richards, N.; Evans, D.; Price, D.E.; Bain, S.C.; Stephens, J.W.

doi:10.1016/j.pcd.2009.11.001

« Previous Next »Primary Care Diabetes
Volume 4, Issue 1 , Pages 57-60, April 2010

Clinical experience with exenatide in a routine secondary care diabetes clinic

B. Natarajan
- Department of Diabetes & Endocrinology, Morriston Hospital, ABM University NHS Trust, Swansea, Wales, UK
M. Edavalath
- Department of Diabetes & Endocrinology, Morriston Hospital, ABM University NHS Trust, Swansea, Wales, UK
J. Davies
- Department of Diabetes & Endocrinology, Morriston Hospital, ABM University NHS Trust, Swansea, Wales, UK
L. Jenkins
- Department of Diabetes & Endocrinology, Morriston Hospital, ABM University NHS Trust, Swansea, Wales, UK
N. Marshall-Richards
- Department of Diabetes & Endocrinology, Morriston Hospital, ABM University NHS Trust, Swansea, Wales, UK
D. Evans
- Department of Diabetes & Endocrinology, Morriston Hospital, ABM University NHS Trust, Swansea, Wales, UK
D.E. Price
- Department of Diabetes & Endocrinology, Morriston Hospital, ABM University NHS Trust, Swansea, Wales, UK
S.C. Bain
- Department of Diabetes & Endocrinology, Morriston Hospital, ABM University NHS Trust, Swansea, Wales, UK
- Diabetes Research Group, Institute of Life Sciences, Swansea University, Swansea, Wales, UK
J.W. Stephens
- Department of Diabetes & Endocrinology, Morriston Hospital, ABM University NHS Trust, Swansea, Wales, UK
- Diabetes Research Group, Institute of Life Sciences, Swansea University, Swansea, Wales, UK
- Corresponding author at: Diabetes Research Group, Institute of Life Sciences, Swansea University, Swansea, Wales, UK. Tel.: +44 01792 704078; fax: +44 01792 703214.

Received 26 June 2009; received in revised form 19 November 2009; accepted 20 November 2009. published online 18 December 2009.

Abstract

Exenatide use in type 2 diabetes is limited in routine clinical practice. We examined a cross-section of 90 patients. Mean weight and HBA_1c were 114.9±20.6kg, 10.3±2.1% at initiation; 108.0±15.3kg (p<0.0001), 9.0±2.1% (p<0.001) at 3 months; 109.2±18.2kg (p<0.0001), 9.5±2.3% (p=0.08) at 6 months. Exenatide appears effective in reducing HBA_1c and weight.